However, the evidence to date reveals minimal predictive value
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Gentle swirling is preferred
With Food: Creates a buffer to protect your stomach lining
however, the same mechanism is often the culprit behind digestive discomfort such as bloating, constipation, diarrhea, and abdominal cramping
Within days of my first injection, the screeching food noise that had always plagued me became a faint whisper